🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 04/06/2004 | 8,92 | 9,25 | 8,76 | 9,25 | +5,11% | 5,49% | 652.800 |
| 03/06/2004 | 9,12 | 9,23 | 8,80 | 8,80 | -3,72% | 4,71% | 513.400 |
| 02/06/2004 | 9,21 | 9,34 | 9,01 | 9,14 | -1,40% | 3,58% | 516.100 |
| 01/06/2004 | 9,25 | 9,28 | 8,90 | 9,27 | +5,34% | 4,11% | 789.900 |
| 28/05/2004 | 8,75 | 8,86 | 8,66 | 8,80 | +0,34% | 2,29% | 252.600 |
| 27/05/2004 | 8,96 | 9,09 | 8,57 | 8,77 | -1,90% | 5,80% | 600.400 |
| 26/05/2004 | 8,73 | 8,94 | 8,54 | 8,94 | +3,35% | 4,58% | 743.000 |
| 25/05/2004 | 8,68 | 8,85 | 8,56 | 8,65 | -1,59% | 3,34% | 722.100 |
| 24/05/2004 | 8,69 | 8,88 | 8,56 | 8,79 | +1,15% | 3,68% | 811.500 |
| 21/05/2004 | 8,72 | 9,00 | 8,06 | 8,69 | +6,36% | 10,78% | 2.147.000 |
| 20/05/2004 | 8,35 | 8,72 | 8,17 | 8,17 | -1,57% | 6,59% | 814.200 |
| 19/05/2004 | 8,43 | 8,52 | 8,17 | 8,30 | -1,54% | 4,15% | 1.099.200 |
| 18/05/2004 | 8,30 | 8,58 | 8,11 | 8,43 | +2,55% | 5,66% | 784.600 |
| 17/05/2004 | 8,27 | 8,75 | 8,00 | 8,22 | -1,08% | 9,07% | 800.100 |
| 14/05/2004 | 8,51 | 8,76 | 8,24 | 8,31 | -2,24% | 6,11% | 809.700 |
| 13/05/2004 | 9,00 | 9,05 | 8,50 | 8,50 | -5,13% | 6,11% | 538.400 |
| 12/05/2004 | 8,61 | 9,00 | 8,34 | 8,96 | +2,17% | 7,67% | 642.800 |
| 11/05/2004 | 8,82 | 9,01 | 8,65 | 8,77 | +1,04% | 4,08% | 412.700 |
| 10/05/2004 | 8,53 | 9,20 | 8,29 | 8,68 | +1,76% | 10,67% | 1.185.100 |
| 07/05/2004 | 8,91 | 9,10 | 8,53 | 8,53 | -4,26% | 6,40% | 729.100 |
| 06/05/2004 | 9,27 | 9,32 | 8,73 | 8,91 | -4,19% | 6,36% | 518.300 |
| 05/05/2004 | 9,13 | 9,50 | 9,11 | 9,30 | +0,65% | 4,27% | 552.600 |
| 04/05/2004 | 9,24 | 9,54 | 8,81 | 9,24 | +2,44% | 7,90% | 2.461.500 |
| 03/05/2004 | 8,68 | 9,29 | 8,60 | 9,02 | +4,40% | 7,95% | 759.800 |
| 30/04/2004 | 9,10 | 9,20 | 8,64 | 8,64 | -5,05% | 6,15% | 818.600 |
| 29/04/2004 | 9,12 | 9,34 | 8,98 | 9,10 | -0,22% | 3,95% | 908.000 |
| 28/04/2004 | 9,39 | 9,50 | 8,99 | 9,12 | -3,18% | 5,43% | 971.300 |
| 27/04/2004 | 9,28 | 9,64 | 9,14 | 9,42 | +3,52% | 5,39% | 2.129.500 |
| 26/04/2004 | 9,15 | 9,33 | 8,92 | 9,10 | +0,78% | 4,48% | 702.200 |
| 23/04/2004 | 9,26 | 9,37 | 8,82 | 9,03 | -2,38% | 5,94% | 792.800 |